35 results about "SUBCUTANEOUS TUMOR" patented technology

The invention relates to the technical field of biological medicines, in particular to a CKAP4-targeted tumor antigen peptide, a vaccine and application of the CKAP4-targeted tumor antigen peptide. The invention provides a high-immunogenicity tumor antigen peptide RLTELTKSI targeting human and mouse homologous CKAP4 protein, and the tumor antigen peptide and a vaccine thereof can realize efficient killing of CKAP4 positive tumor cells and remarkable inhibition of CT26 subcutaneous tumor by activating specific CD8 + T cell immune response. The traditional single-target limitation is broken through, the co-expression characteristic of CKAP4 in tumor cells and immunosuppressive cells (TAM / TAN) is utilized, a double-target and double-channel mechanism is initiated, and the immunosuppressive state of cold tumors is effectively reversed by inducing T cells to synchronously kill tumor cells and remodel an immune microenvironment. According to the technology, CKAP4 is expanded from an antibody target to a T cell vaccine target, lasting specific CTL response can be stimulated, the off-target risk of antibody treatment is avoided, a universal treatment scheme can be provided for solid tumors, and the clinical transformation potential and the treatment broad spectrum are remarkably improved.

The invention relates to the technical field of medicines, and discloses a bifidobacterium longum strain GZBAI 01 and application thereof in degradation of benzoic acid and prevention or treatment of colorectal cancer. The strain is separated from faeces of healthy people, genomics identification is carried out, the metabolic profile of the strain is measured through metabonomics, the strain can convert benzoic acid with carcinogenic risk into protocatechuic acid with antitumor activity through unique metabolic capability, meanwhile, the function of regulatory T cells (Treg) in tumor drainage lymph nodes can be inhibited, differentiation of CD8 + T cells is promoted, and the tumor drainage lymph nodes can be inhibited. Therefore, the colorectal cancer is prevented through double ways of eliminating cancerogen and generating therapeutic agents. A colorectal cancer mouse model and a subcutaneous tumor mouse model verify that the strain can significantly reduce the number and volume of tumors, and shows a benzoic acid conversion effect superior to that of other strains in vivo and in vitro, and a new way is provided for prevention and treatment of colorectal cancer.

The invention relates to application of lactobacillus muricatum in preparation of a medicine for treating oral cancer, the oral cancer is oral squamous cell carcinoma, a C57BL / 6 mouse tongue squamous cell carcinoma model induced by a 4-NQO water drinking method and a C3H / HeN subcutaneous tumor model inoculated by SCC7 tumor cells are constructed, and the lactobacillus muricatum has a remarkable inhibition effect on the oral cancer; experiments prove that the number / area / volume / weight of tumors is remarkably reduced by the lactobacillus muricatum, tumor marginal infiltration and abnormal karyokinesis are effectively inhibited, the expression quantity of tumor proliferation markers is remarkably reduced, and obvious pathological changes do not appear in main organs (heart, liver, spleen, lung and kidney) of mice. The method for minimally invasive injection of the lactobacillus muricatum into the oral squamous cell cancer tumor is safe, drug resistance is not easily induced, the treatment scheme is standardized, and the method has good clinical application potential.

Phytol (PHY) is a metabolite of plant chlorophyll, is wide in source and is a chain-like diterpenoid substance consisting of four isoprene units, and the phytol ingested by animals is subjected to oxidative metabolism in vivo, so that not only can energy be provided for the animals, but also the growth of the animals can be promoted, and the growth of the animals can be promoted. Moreover, the phytol and the phytanic acid metabolite of the phytol can also be used as signal molecules to participate in glycolipid metabolism and adipocyte differentiation regulation processes, but people cannot directly take the phytol and the phytanic acid from the nature. The effect of phytol in the generation and development of tumors still has huge unknown property. According to the research, the influence of the phytol and the derivative thereof on the growth of colon cancer, breast cancer and melanoma is detected through an in-vitro experiment CCK-8 (Cell Count Kit 8) and an in-vivo experiment such as a mouse subcutaneous tumor model, and the phytol and the derivative thereof are found to be capable of remarkably inhibiting the growth of colon cancer, breast cancer and melanoma and have no obvious toxic and side effects on heart, liver and kidney functions.

The present application relates to the application of Hhex agonists in promoting anti-tumor immunity. Specifically, the present application provides a pharmaceutical composition comprising chenodeoxycholic acid and an anti-PD-1 antibody. The present application also provides the use of chenodeoxycholic acid and an anti-PD-1 antibody in the preparation of a drug for promoting anti-tumor immunity. In addition, the present application also provides the use of chenodeoxycholic acid and an anti-PD-1 antibody in the preparation of a drug for treating tumors. The present application uses chenodeoxycholic acid to improve the tumor immune microenvironment and uses it to treat subcutaneous tumors, further verifying that the application of chenodeoxycholic acid can improve the tumor immune microenvironment.

The application discloses a nano-antibody (also known as single-domain antibody) conjugated photosensitizer targeting HER2, a preparation method of the photosensitizer and application of the photosensitizer in tumor photodynamic therapy. The photosensitizer is shown in a general formula (I). In the photosensitizer, the nano-antibody (N HER2 ) serving as a targeting ligand is connected with a photosensitive moiety (PS) through a catalytic reaction mediated by a transglutaminase (MTGase). Research finds that the anti-HER2 nano-antibody conjugated photosensitizer molecule has good cell killing selectivity and tumor enrichment capacity, and can remove a subcutaneous tumor of a mouse with high HER2 expression in one administration. HER2 -PEG 1K -PS (I).

The present invention discloses that cancer cells secrete succinate into extracellular milieu, which increases macrophage migration and mediates TAM polarization. Furthermore, succinate induces cancer cell EMT, enhances cancer cell migration, and promotes cancer metastasis in murine models. It is indicated in the present invention that serum succinate concentration is elevated in patients with lung cancer when compared to healthy subjects. It implies that during cancer development and progression, cancer cells release a large quantity of succinate into the circulation. As shown in the present invention, serum succinate has a high discriminatory power, it represents a new class of circulating oncometabolite with potential value for predicting NSCLC. Furthermore, as elevation of succinate level in LLC tumor model is accompanied by increased TAMs in the subcutaneous tumors and enhanced cancer metastasis, serum succinate may be a useful therapeutic biomarker for NSCLC treatment. The present invention also provides an anti-succinate antibody that can serve as a cancer therapeutic agent.

The application provides a kind of intracellular near-infrared light catalysis nano-assembly and preparation method and application, the nano-assembly of the application involves three components, one is the photocatalyst with near-infrared absorption, simultaneously as photothermal reagent, two is NO release base element, three is amphiphilic block copolymer polyethylene glycol block polycaprolactone.By fast nano precipitation method, amphiphilic block copolymer is self-assembled in aqueous solution to load photocatalyst and NO release base element, obtain nano-assembly, the photocatalyst molecule in the nano-assembly can be used as photo-oxidation and reduction catalyst under light condition to activate NO donor molecule to release NO, can also consume intracellular NADH, can also produce heat, can effectively kill triple-negative breast cancer tumor cells, and effectively inhibit tumor growth in mouse subcutaneous tumor model.

This invention belongs to the field of tumor biology and drug screening technology, specifically disclosing a human EGFR mutation-driven mouse primary lung cancer cell line, its construction method, and its applications. The cell line, ZST-1, is a human EGFR (L858R / T790M) mutation-driven lung cancer cell line derived from mouse primary lung cancer. It is stable, capable of subcutaneous tumor formation in C57BL / 6 mice, and simultaneously expresses Luciferase and tdTomato reporter genes. Its construction method includes obtaining transgenic mice, virus-induced tumor formation, continuous in vivo passage in nude mice, and in vitro culture and screening steps. This cell line can be applied to in vitro screening and efficacy evaluation of human EGFR mutation-targeting drugs, research on EGFR-TKI resistance mechanisms, tumor bioluminescence imaging and fluorescence tracing, and in vivo tumorigenesis and efficacy experiments in an immune-intact C57BL / 6 background.

The invention discloses an imaging window device applied to subcutaneous tumors, and belongs to the technical field of medical apparatuses and instruments. By designing the subcutaneous window comprising the imaging observation ring and the window fixing frame arranged outside the imaging observation ring in a sleeving mode, the weight of the dorsal ridge window is greatly reduced, the burden of a mouse is relieved, and great influences on physiological activities of the mouse can be effectively avoided. By arranging the fixing support detachably connected with the subcutaneous window, the subcutaneous window is fixed in the imaging platform in the imaging process, imaging artifacts caused by respiratory movement of a mouse are reduced, long-time positioning imaging can be achieved, and the imaging effect is better. The subcutaneous window is made of titanium alloy, good biocompatibility is guaranteed, long-term change of skin defect or subcutaneous tumor models can be observed through the window for a long time, blood supply cannot be damaged, a part of soft sponge can be attached to the imaging face of the window, the situation that the skin is prone to necrosis during suturing is avoided, and the real microenvironment is reflected more truly.

The invention belongs to the technical field of nano biomedicine, and particularly discloses a preparation method of a galangin-loaded bionic nano dendritic cell (DCs) vaccine and application of the galangin-loaded bionic nano dendritic cell (DCs) vaccine in ovarian cancer treatment. The inner core of the vaccine is galangin (GA)-loaded polylactic acid-glycolic acid copolymer (PLGA) nanoparticles, and the shell of the vaccine is formed by coating a DCs film carrying tumor antigens. The nano DC vaccine retains the antigen presentation function of natural DCs, and the GA loaded on the nano DC vaccine can induce tumor cells to generate immunogenic cell death. By means of the design, the vaccine can efficiently load specific tumor-associated antigens, and the homing capacity of the vaccine to lymph nodes and tumor microenvironments is remarkably enhanced. Experiments show that GA-NPs (at) DCV is used for treating subcutaneous tumor and in-situ ovarian cancer mouse models.

This invention discloses a combination drug of Akkermansia and an EET homologue and its uses, relating to the field of biomedical technology. Specifically, the combination drug of this invention comprises: A1) a first active ingredient, the first active ingredient comprising Akkermansia myxophilus; and A2) a second active ingredient, the second active ingredient comprising at least one of 14,15-epoxyeicosatetrienoic acid (14,15-EET) or an isomer of 14,15-epoxyeicosatetrienoic acid, a pharmaceutically acceptable salt, an ester, or a prodrug. The combination drug of this invention exhibits excellent anti-inflammatory and anti-tumor effects in LPS-induced inflammation models and LLC subcutaneous tumor models. The synergistic index SI > 1 calculated using the Bliss independent model indicates a good synergistic effect, and it can be used for the prevention, treatment, and prognostic improvement of non-small cell lung cancer.

The invention relates to the field of biological pharmacy, and discloses an application of an FABP5 protein target inhibitor in preparation of a product for treating cancers, and the inhibitor is apigenin 7-O-malonyl glucoside. The invention provides a novel cancer cell targeting therapeutic drug, the inhibitor inhibits proliferation of renal clear cell adenocarcinoma and subcutaneous tumor-bearing through precise targeting of FABP5 protein and can be applied to preparation of anti-renal clear cell adenocarcinoma and subcutaneous tumor-bearing drugs, and apigenin 7-O-malonyl glucoside can be used in combination with a PD-1 monoclonal antibody, so that the treatment effect is good. The inhibition effect is better, and a new treatment scheme is provided for the treatment of the kidney cancer.

The invention discloses application of a hydrogel microneedle capable of being implanted into an abdominal cavity in colorectal cancer abdominal wall infiltration focus, and relates to the field of medicine. The traditional Chinese medicine composition is applied to clinical treatment of rectal cancer abdominal wall infiltration lesions, and a mouse subcutaneous tumor model and the abdominal wall infiltration lesions are verified, and the specific application method comprises the following steps that 1, after a mouse is subjected to general anesthesia, the abdomen of the mouse is opened, and the position of the abdominal wall infiltration lesions is detected and determined; step 2, clamping the sterilized micro-needle sheet by using noninvasive forceps and feeding the sterilized micro-needle sheet into an abdominal cavity; 3, attaching the microneedle substrate to the surface of a focus under direct view, and pressing to enable the needle body to penetrate through the peritoneum; and 4, flushing with normal saline to confirm that the microneedle is fixed, withdrawing the instrument, and suturing the incision. The microneedle physically penetrates through the surface layer of the peritoneum, the medicine is directly delivered to the deep layer of an infiltrating focus, the problem of low efficiency caused by the peritoneum barrier in the traditional therapy is solved, and the GelMA / hyaluronic acid hydrogel is gradually swelled and degraded in body fluid, so that collagenase, a macrophage scavenger and an anti-tumor medicine are continuously released, and the local effective concentration can be maintained for more than two weeks.

This invention discloses an immune cell with enhanced anti-tumor effect, its preparation method, and its application. Experiments using this invention show that... SERTAD1 CD8 gene overexpression + T cells can enhance their function in anti-tumor immunotherapy. SERTAD1 Gene overexpression can downregulate CD8 + The expression of immune checkpoint molecules on T cells upregulates the expression of mRNAs of tumor-killing cytokines. In the MC38-OVA subcutaneous tumor model, Naïve CD8 cells were extracted from OT-I mice. + T cells were infected with a virus to overexpress SERTAD1, followed by adoptive transfer to mice. The results showed that SERTAD1 overexpression enhanced CD8 expression. + T cells kill MC38-OVA cells, inhibit the growth of MC38-OVA tumor cells, and overexpress SERTAD1 CD8. + The tumor volume and weight in the T-cell adoptive group were significantly smaller than those in the control group.

This invention belongs to the field of biomedical technology, specifically relating to a Pt 2+ - Carbon dot@protoporphyrin sonodynamic drug delivery system, its preparation method and application, by loading Pt onto the surface of carbon dots 2+ Modification layer, to obtain Pt 2+ After carbon dots are formed, protoporphyrin is loaded onto them to obtain a carbon dot core with Pt loaded on the carbon dot surface. 2+ Modification layer, in Pt 2+ A sonodynamic drug delivery system with a protoporphyrin-modified layer loaded on the outside of the modified layer can be used in anti-tumor drugs to screen liver cancer cells and normal cells. It has good biocompatibility and significant in vivo sonodynamic anti-tumor effects. It can promote the generation of reactive oxygen species, target and remain in the subcutaneous tumor site in vivo for a long time, increase the mortality rate of cancer cells, and inhibit tumor growth. In a 3D constructed in vitro hepatocellular tumor microenvironment model, this drug delivery system still has superior sonodynamic therapeutic effects.

The invention discloses a PD-1 / PD-L1 immunotherapy acquired drug-resistant mouse subcutaneous tumor model construction method based on in-vivo multi-dimensional immune landscape evolution, and relates to the field of animal model construction. Comprising the following steps: preparing tumor cells: resuscitating and amplifying an MC38 colonic adenocarcinoma cell strain, and preparing a single-cell suspension; establishing a basic model: inoculating the MC38 single-cell suspension under the skin of a homologous C57BL / 6 mouse, and establishing a tumor-bearing mouse model; drug resistance induction and screening: after the tumor grows to a predetermined volume, applying continuous treatment pressure of an anti-PD-1 or anti-PD-L1 antibody to the tumor-bearing mouse. Firstly, the tumor volume of mice in a treatment group is compared with the average volume of a control group at the same time point, response mice with the tumor volume obviously smaller than that of the control group are screened out, and primary drug-resistant individuals are excluded. Performing dynamic immune monitoring sampling; and processing and analyzing the sample. The preclinical model has the characteristics of repeatability and dynamic monitoring, and overcomes the defects of the existing preclinical model.

The invention relates to a multi-target molecular ligand as well as a preparation method and application thereof. The multi-targeting molecular ligand disclosed by the invention aims at prostate cancer and bone metastasis thereof, and the ligand simultaneously contains a polypeptide chain Glu-urea-Lys (ACUPA) capable of being recognized by a prostate specific membrane antigen (PSMA), is used for targeting diphosphoric acid of hydroxyapatite nanocrystals in bones, and is also combined with an anisidine fragment which is specifically combined with a Sigma-1 receptor. The multi-target molecular ligand can efficiently mark radionuclide and has excellent radiation stability, cell and animal experiments prove that the multi-target molecular ligand can be efficiently taken by PSMA positive prostate cancer RM-1 cells, RM-1 subcutaneous tumor models and RM-1 tibial metastatic tumor models, and can be used for developing diagnosis and treatment of PSMA positive prostate cancer and bone metastasis thereof, and diagnosis and treatment integration is achieved.

The invention belongs to the technical field of biological medicine, and relates to application of H1FX as a therapeutic target and application of three compounds as H1FX inhibitors in preparation of drugs for preventing and / or treating prostatic cancer. Experimental results show that up-regulation of H1FX expression level can promote proliferation of prostate cancer cells, and knock-down of H1FX can inhibit proliferation of prostate cancer cells. H1FX expression up-regulation can significantly promote generation and development of prostate cancer cell line nude mouse subcutaneous tumor formation. Researches show that the three compounds are specifically combined with H1FX, and proliferation of prostate cancer cells and growth of subcutaneous tumors of nude mice with prostate cancer cell strains are inhibited. Therefore, the invention provides a new target for the design of new anti-prostatic cancer drugs, and provides a new thought for the development and preparation of prostatic cancer prevention and / or treatment drugs.

This invention belongs to the field of biomedical technology and relates to the application of a diagnostic kit for early gastric adenocarcinoma using gastric tumor stem cells that highly express PDZK1IP1 based on cellular characteristics and spatial transcriptional features. This invention is the first to propose a novel diagnostic method for early gastric adenocarcinoma using gastric tumor stem cells that highly express PDZK1IP1 based on cellular characteristics and spatial transcriptional features. It also clarifies for the first time the functional phenotype and biological significance of PDZK1IP1 in gastric adenocarcinoma cells. The results of this invention show that inhibiting PDZK1IP1 can weaken the proliferation and tumor spheroid formation abilities of gastric cancer cells, and further inhibit the growth rate and size of subcutaneous tumors in mice, suggesting that PDZK1IP1 could serve as a new target for gastric cancer treatment, providing a new strategy for the clinical treatment of gastric adenocarcinoma.

This invention relates to a compound and its preparation method, a modular peptide nanovaccine and its preparation method and application, and relates to the pharmaceutical field. The chemical structural formula of the compound is shown in Formula I. This invention provides a compound containing an mPEG-PLA structure, a protoporphyrin structure chelated with cobalt ions, and a β-cyclodextrin structure, endowing it with excellent binding ability to peptides and excellent loading capacity with adjuvants, achieving co-delivery of peptides and adjuvants. Based on this, this invention also provides a modular peptide nanovaccine with high peptide loading rate and "plug-and-play" characteristics. It can significantly inhibit tumor growth in a B16 subcutaneous tumor model, providing an efficient and flexible technical platform for the prevention of melanoma and other tumors and the clinical translation of peptide vaccines, with broad application prospects.

The invention discloses a head and neck cancer chemotherapy recurrence animal model and a construction method and application thereof, and relates to the technical field of animal model construction. Comprising the following steps: S1, culturing head and neck cancer tumor cells with fluorescence labels under an in-vitro condition; s2, subcutaneously planting the head and neck cancer tumor fluorescent cells in a groin part of a model animal; s3, 5 days after planting, imaging and observing subcutaneous tumor formation of the model animal, and performing periodic chemotherapy; s4, monitoring through a living body imaging system until a tumor fluorescence signal basically disappears, and determining tumor regression; s5, stopping chemotherapy, continuing feeding for 5-6 weeks, and observing the tumor recurrence condition of the model animal to obtain the head and neck cancer chemotherapy recurrence animal model. The method is easy and convenient to operate, short in experimental period and low in consumption, non-invasive dynamic monitoring can be achieved through the living body imaging technology, the variability of the result is small, the success rate is high, and an ideal platform is provided for head and neck cancer recurrence research and drug screening.

The application belongs to the technical field of biological medicine, and particularly relates to application of ILDR3 gene and / or ILDR3 protein in preparation of medicines for preventing and / or treating tumors and products for diagnosing tumors. The application research finds that the ILDR3 gene and / or ILDR3 protein is lowly expressed in cancer tissues of colorectal cancer patients and colorectal cancer cells, and knocking out the ILDR3 gene promotes proliferation and migration and invasion of the colorectal cancer cells and tumor occurrence and development. Based on this, the ILDR3 gene and / or ILDR3 protein is overexpressed, so that good inhibition effect on proliferation and migration and invasion of the colorectal cancer cells and growth of subcutaneous tumors is achieved, and the purpose of inhibiting the colorectal cancer is achieved. The method of the application provides a new treatment target for prevention and / or treatment of the colorectal cancer, provides application of the ILDR3 gene as a target gene for preventing / treating / diagnosing the colorectal cancer, and provides a new strategy and direction for prevention and / or diagnosis and / or treatment of the colorectal cancer.

The application discloses a kind of composite nanoparticles for chemiluminescence excitation light power treatment and its preparation method and application.The composite nanoparticles include following three raw material components: chemiluminescence substrate, amphiphilic molecule and photosensitizer;The composite nanoparticles are chemiluminescence substrate and photosensitizer are co-encapsulated in the nanoparticle of amphiphilic molecule.The composite nanoparticles can respond to the overexpression of hydrogen peroxide in vivo, start chemiluminescence excitation photodynamic therapy, meanwhile, excited state photosensitizer can catalyze the oxidation of overexpressed NADH in tumor cell and generate H2O2 in situ, provide H2O2 source for chemiluminescence, promote the continuous performance of chemiluminescence.Therefore, the composite nanoparticles show efficient chemiluminescence excitation photodynamic activity to cancer cells, and have excellent therapeutic effect on subcutaneous tumor and lung metastasis tumor at the level of living body.

The invention discloses application of liensinine perchlorate in preparation of a medicine for treating lung cancer, and the liensinine perchlorate is used for preparing the medicine for treating the lung cancer or used for preparing a sensitizing medicine for immunotherapy of the lung cancer, and the lung cancer comprises large-cell lung cancer, small-cell lung cancer, lung adenocarcinoma or lung squamous carcinoma. The liensinine perchlorate or the pharmaceutically acceptable solvate thereof is used as an active ingredient, and the prognosis of a patient is improved by inhibiting the growth of lung cancer cells and improving the immunotherapy curative effect of lung cancer, so that the survival rate of five years is improved. Cell experiments show that liensinine perchlorate inhibits the growth of lung cancer cells in a concentration gradient dependent manner, animal experiments show that liensinine perchlorate can significantly inhibit the growth of subcutaneous tumors, and the growth of lung cancer can be further inhibited in combination with PD-L1 monoclonal antibody treatment. In addition, liensinine perchlorate is easy to obtain, soluble in water, high in safety and capable of being directly taken orally, and a novel safe and effective method for lung cancer treatment and lung cancer immunotherapy sensitization is provided.

The invention provides a near-infrared AIE fluorescent probe as well as a preparation method and application thereof. The fluorescent probe has obvious AIE property, aggregation-induced emission (AIE) effect and good light stability, can realize seven-day imaging of CAR-T cells, can target CAR-T cell mitochondria, cannot leak to other cells, and avoids false positive results. Meanwhile, the probe has good biocompatibility, does not influence CAR-T cells to secrete key cell factors IFN-gamma, and does not damage the killing function of the CAR-T cells on tumor cells. In a small animal living body level, the probe N-6 is used for tracing CD19 CAR-T cells in a Raji subcutaneous tumor model mouse, a result shows that a fluorescence signal can be continuously observed for 7 days, and the CAR-T cells are continuously enriched in tumor tissues and liver tissues, which indicates that the probe N-6 can monitor the dynamic distribution process of the CAR-T cells in vivo in real time.

The present disclosure demonstrates that cancer cells secrete succinate into the extracellular environment, which in turn increases the migration ability of macrophages and mediates cancer-associated macrophage polarization. In mouse models, succinate not only induces cancer cell epithelial-mesenchymal transition, enhances cancer cell migration ability, but also promotes cancer metastasis. The present disclosure also indicates that the concentration of succinate in the serum of lung cancer patients is higher than that of healthy subjects, which means that cancer cells release a large amount of succinate into the circulatory system during the development and progression of cancer. As shown in the present disclosure, serum succinate has high discriminative power and can be used as a new class of circulating metabolic carcinogen for predicting non-small cell lung cancer. In addition, in LLC tumor models, the increase in succinate concentration is accompanied by an increase in TAMs in subcutaneous tumors and more severe cancer metastasis, so the serum succinate may be an effective therapeutic biomarker for treating NSCLC. Therefore, the present disclosure also provides an anti-succinate antibody that can be used as a cancer therapeutic agent.

The invention discloses grape-derived exosome-like nanoparticles as well as a preparation method and application thereof. The GELNs are obtained by crushing fresh grape skin and combining gradient centrifugation and ultracentrifugation technology separation, the particle size is about 200 nm, the form is uniform, and the GELNs can be stably dissolved in PBS and stored at 4 DEG C for at least one month. Experiments prove that the GELNs can be efficiently taken by nasopharyngeal carcinoma cells, and can be used as a natural carrier to effectively load resveratrol, so that the anti-tumor effect of the GELNs is remarkably enhanced. An in-vitro cell experiment shows that the GELNs-resveratrol compound can obviously inhibit proliferation and migration of nasopharyngeal carcinoma cells; an in-vivo nude mouse subcutaneous tumor model further proves that the compound can effectively inhibit tumor growth and has good biocompatibility and targeting property. The invention provides a plant source nano-drug platform which is simple in process, high in safety, low in toxicity and high in efficiency, and has a wide application prospect in targeted therapy of nasopharyngeal carcinoma.

The invention belongs to the technical field of cancer cell lines, and discloses a mouse-derived oral squamous cell cancer cell line, which is named as C57BL / 6N mouse tongue squamous cell cancer cells MTSCC Mus musculus, is preserved in China Center for Type Culture Collection on February 18, 2025, and has a preservation number of CCTCC NO: C202562. The invention also discloses an application of the cell line in preparation of an oral squamous cell carcinoma tumor model. The subcutaneous tumor constructed by the cell line is high in tumor formation rate, short in tumor formation time and slow in development, a longer time window is provided for scientific research, the constructed subcutaneous tumor is complete in immune microenvironment and large in immune cell infiltration, and the subcutaneous tumor has clear matrix components.

A method for non-invasively identifying a location of a subcutaneous tumor comprising: providing a patient with a possible subcutaneous tumor; providing a detector comprising one or more radio-frequency (RF) planar resonant loop sensors, each sensor comprising a planar resonant loop and an element disposed within and co-planar with a loop formed by the planar resonant loop; creating a first localization map of resonant frequencies of an area including the possible tumor using the detector; and creating a second localization map of |s11| reflection coefficients of the area including the possible tumor using the detector.